Cas:934236-40-5 Methyl 2-amino-1,3-oxazole-5-carboxylate manufacturer & supplier

We serve Chemical Name:Methyl 2-amino-1,3-oxazole-5-carboxylate CAS:934236-40-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Methyl 2-amino-1,3-oxazole-5-carboxylate

Chemical Name:Methyl 2-amino-1,3-oxazole-5-carboxylate
CAS.NO:934236-40-5
Synonyms:Methyl 2-amino-1,3-oxazole-5-carboxylate;5-Oxazolecarboxylic acid, 2-amino-, methyl ester
Molecular Formula:C5H6N2O3
Molecular Weight:142.113
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:273.4±32.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.531
PSA:78.35000
Exact Mass:142.037842
LogP:-0.20

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Methyl 2-amino-1,3-oxazole-5-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Oxazolecarboxylic acid, 2-amino-, methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Oxazolecarboxylic acid, 2-amino-, methyl ester Use and application,5-Oxazolecarboxylic acid, 2-amino-, methyl ester technical grade,usp/ep/jp grade.


Related News: We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally. Methyl 2-amino-1,3-oxazole-5-carboxylate manufacturer This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them. Methyl 2-amino-1,3-oxazole-5-carboxylate supplier We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally. Methyl 2-amino-1,3-oxazole-5-carboxylate vendor The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. Methyl 2-amino-1,3-oxazole-5-carboxylate factory Retrogenix��s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses.